A Phase 1 dose escalation study of CND 106
Latest Information Update: 13 Sep 2024
At a glance
- Drugs CND 106 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- 13 Sep 2024 New trial record
- 09 Sep 2024 According to a Candid Therapeutics media release, company has completed Phase 1 dose escalation studies for CND106 and CND261 drug candidates.